Cell surface presence of the coxsackie and adenovirus receptor (CAR) is considered a crucial prerequisite for the uptake of attenuated adenovirus. In cancers, however, a frequent loss of CAR has been noted potentially hampering the success of adenovirus-based therapy. In esophageal Barrett's carcinomas and its precursor lesions CAR presence has not been systematically determined yet. Immunohistochemical assessment in tissue specimens of 111 patients revealed CAR-positivity in all cases of Barrett's esophagus, including various degrees of intraepithelial neoplasia. In contrast, no considerable CAR presence was seen in squamous esophageal epithelium. Among Barrett's carcinomas, 93% displayed CAR presence, whereas CAR-negativity was observed preferentially in advanced cancers. Aiming to evaluate whether this loss of CAR impacts tumor-biologic properties of esophageal adenocarcinomas we studied cell lines OE19 and OE33 and observed an increased proliferation, migration and invasion upon siRNA-mediated functional CAR knock down. In conclusion, our results indicate that CAR may provide a valuable target for adenovirus-based therapy of Barrett's carcinomas and its precursor lesions. These data do also suggest that CAR does not contribute substantially to carcinogenesis in Barrett's esophagus, however, it may be speculated that loss of CAR promotes tumor progression in advanced stages of Barrett's carcinomas.
Introduction
The coxsackie and adenovirus receptor (CAR), a transmembrane component of the tight junctions (TJs) complex, represents the primary viral attachment site on the surface of epithelial cells and marks a prerequisite for cellular virus uptake. 1, 2 Therefore, CAR presence is considered a critical determent for the efficacy of adenoviruses-based therapies. Hereby, attenuated adenoviruses, either replication-incompetent viruses delivering therapeutic genes or viruses that replicate restrictedly in certain cell types, may be employed, for example, for the treatment of malignant diseases. 3 However, in several human cancers particularly in those displaying poor differentiation, advanced disease stages and a poor clinical outcome, a reduced presence of CAR as been documented. [4] [5] [6] [7] [8] Functionally this loss of CAR has been found to impair intercellular adhesion, promote proliferation, migration, and invasion of cancers, leading to the hypothesis of a tumor-suppressive role of CAR. [9] [10] [11] [12] [13] In contrast, it has also been speculated that CAR promotes the development of adenocarcinomas, as elevated CAR level were found in early stage breast cancer and breast cancer precursor cell lines. 14, 15 Barrett's esophagus (BE) represents the acquired replacement of squamous epithelium lining the distal esophagus by columnar cells, also referred to as 'specialized intestinal metaplasia.' BE is established as a precancerous condition: Barrett's carcinoma (BC) develops by several grades of dysplasia, also referred to as intraepithelial neoplasia (IN) . 16 Among various genetic events a disturbed balance of TJ proteins, which regulate tissue integrity and paracellular transport, is believed to promote the development of BC. [17] [18] [19] In line with this hypothesis complex alterations of TJ expression in BE and BC compared to esophageal squamous epithelium have been observed: claudin-1 and claudin-5 are downregulated in BE 19, 20 whereas for claudin-2, -3, -4 and -7 an upregulation has been noted, in particular in highgrade IN and BC. 17, 19, 21 These data suggest that downregulated TJ proteins might facilitate inhibitory functions, whereas upregulated TJs may promote the progression of BE. However, despite these findings a detailed understanding of how TJ contribute to malignant transformation and disease progression in BE and BC, is still lacking.
The expression and potential function of CAR in BE and associated neoplasia have not been studied systematically yet. Reports on CAR immunopositivity in BE are limited to a single patient. 22 Therefore, the objective of this study was to investigate presence and potential function of CAR in BE and associated neoplasia, aiming to evaluate the potential use of CAR as target 'biomarker' for diagnosis and therapy of these conditions.
Materials and methods

Study population and tissue examined
Biopsy tissue specimens were obtained during upper gastrointestinal (GI) endoscopy from 10 patients (five men; mean age 60 years, range 36-82) with previously diagnosed BE who had undergone endoscopic surveillance according to current standards during 2002 at the Department of Internal Medicine II, Technical University of Munich, Munich, Germany. Written informed consent for immunohistochemical evaluation of the samples was obtained from all patients. The procedure included four quadrant biopsies starting at the proximal cardia folds, every 2 cm up to the proximal BE margin, which in most cases contained adjacent squamous epithelium. This normal squamous epithelium from the most proximal biopsies was taken as control and was present in at least one biopsy from each patient. The final histopathologic diagnosis from these specimens included: BE without neoplasia (n ¼ 28), indefinite for IN (n ¼ 8), low-grade IN (n ¼ 7), high-grade IN (n ¼ 2), and BC confined to the mucosa (n ¼ 4). All biopsies were reevaluated by two experienced GI histopathologists (MS, IB). The four cases of BC all represented mucosal cancer as proven by subsequent endoscopic mucosal resection.
To evaluate CAR expression in advanced cancer stages, we additionally investigated tumor samples of 101 patients (95 men; mean age 65 years, range 33-82) with locally progressed esophageal adenocarcinoma. These patients underwent esophageal resection without preoperative radio-or chemotherapy between 1991 and 2003 at the Department of Surgery, Technical University of Munich, Germany. Histopathological workup of the specimens was performed using standard methods. All tumor samples were reviewed by an experienced GI pathologist (MS). Tumor stage was determined according to the current TNM classification, tumor grade according to World Health Organization criteria. 23, 24 Accordingly, 15 cases were categorized as pT1 (mucosa), 30 as pT1 (submucosa), 20 as pT2 and 36 as pT3. A total of 59 cases were in category pN0 and 42 in category pN1. A total of 6 cases were graded G1, 45 cases G2, and 50 cases G3.
Construction of tissue microarrays and immunohistological investigations
For each of the tissue types of interest paraffin blocks were selected and representative areas were marked on hematoxylin and eosin (H and E)-stained slides. Histological categorization of INs was performed on the basis of H and E-stained slides according to standard criteria. 25, 26 Subsequently, tissue cylinders with a diameter of 0.6 mm were punched from these areas and brought into a recipient paraffin block using a tissue arraying instrument (Beecher Instruments, Silver Spring, MD). In most cases, three cylinders per case and tissue type were introduced into the recipient block. In cases when less tissue was available, only two or one tissue cylinders were arrayed. Sections (4 mm) from the tissue microarrays were mounted on Superfrost Plus slides for the subsequent immunohistochemical study. Hereby, tissue microarray sections were deparaffinized and dehydrated employing standard procedures using rotihistol, isopropanol, and ethanol. Following common antigen retrieval methods including trypsin and microwave treatment in 10 mM citrate buffer (pH 6.0), tissues were blocked in milk and incubated with a primary polyclonal antibody against CAR (1:50, H-300: sc-15405; Santa Cruz Biotechnology Inc., Santa Cruz, CA) for 16 h at 4 1C. Subsequently, sections were incubated in biotinylated goat antirabbit immunoglobulin (1:400; Vector Laboratories, Burlingame, CA), followed by treatment with streptavidin-biotinylated horseradish peroxidase complex (Vectastain Elite ABC kit; Vector Laboratories). Using diaminobenzidine tetrahydrochloride (Sigma-Aldrich, Munich, Germany) sections were developed in hydrogen peroxide/phosphate-buffered saline (PBS) and counterstained with hemalaun. Each run included appropriate positive controls. Negative controls were treated identical as the tumor samples including antigen retrieval procedure except that the primary antibody was replaced by rabbit nonimmune serum. In negative controls no signals were detectable. Samples were classified as: CAR immunonegative (0-4% positive cells) or positive (5-100% positive cells).
Cell culture and generation of stably transfected cell lines For in vitro assays two esophageal adenocarcinoma cell lines: OE19, established from a pathological stage III (Union Internationale Contre le Cancer (UICC)) carcinoma displaying moderate differentiation, and OE33, derived from a pathological stage IIA (UICC) cancer showing poor differentiation, were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS). 27 Chinese hamster ovary (CHO) cells stably transfected with human full length CAR cDNA (CHO-CAR; a kind gift of Dr J Bergelson, Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA) and parental CHO cells were cultured in Ham's F12 medium containing 10% FCS. To permanently inhibit CAR expression a CAR-specific siRNA: CCAA GUACCAAGUGAAGACdTdT and a scrambled siRNA control: CACAAAAGUAUCGCGCAAGdTdT were cloned into the 'pSuper' vector system according to a standard protocol (Oligoengine, Seattle, WA) and transfected into OE19 and OE33 cells using Effectene (Quiagen, Hilden, Germany). Upon cell selection using Puromycin (Sigma-Aldrich) CAR inhibition in pooled cell populations, designated OE19 CAR-negative and OE33
CAR-negative was analyzed by western blotting.
Western blotting
For western blot analysis, cells were washed with ice cold PBS, scraped into lysis buffer (10 mM Tris (pH 7.4), 140 mM NaCl, 2 mM DTT, Complete Mini protease inhibitor; Boehringer, Mannheim, Germany) and sonicated. Equal amounts of protein lysates were loaded on reducing Laemmli gels, immunoblotted with specific antibodies against CAR (H-300: sc-15405; Santa Cruz Biotechnology Inc.), or b-actin (Sigma-Aldrich), and detected employing the electroluminescence system (Amersham Pharmacia, Piscataway, NJ). Protein lysates of CHO and CHO-CAR cells were used as negative and positive controls, respectively.
Assessment of esophageal cancer cell proliferation OE19 CAR-negative , OE33 CAR-negative , and matching control cell lines were seeded onto six-well plates (n ¼ 3 Â 10 5 cells per well) in DMEM containing 10% FCS. After 48 h cell numbers were determined employing a hematocytometer counting chamber (VWR International, Darmstadt, Germany). All experiments were performed in triplicate and repeated at least twice.
Esophageal cancer cell migration Assessment of directed esophageal cancer cell migration was performed employing an 'AP48 48-Well Micro Chemotaxis Chamber' (Neuro Probe, Gaithersburg, MD). Hereby 50 000 cells per well in 50 ml FCS-free media were seeded onto the upper part of the chamber, whereas its lower compartment was filled with media containing 10% FCS-or serum-free media as a control. After 24 h at 37 1C cells migrated through the filter were fixed and stained with crystal violet (0.9 mg ml À1 ) in 10% ethanol. After gentle rinsing with PBS, nonmigrated cells at the upper side of the filter were scraped off. Subsequently, the crystal violet dye retained on the filters was extracted with 10% acetic acid for 5 min at room temperature and colorimetrically measured at 560 nm. All experiments were performed in triplicate and repeated at least twice.
Esophageal cancer cell invasion
The impact of CAR on esophageal cancer cell invasion was analyzed employing 'BioCoat Matrigel Invasion Chambers' (BD Biosciences, Bedford, MA) containing 8 mm pore size polyethylene terepthlate membranes covered with matrigel matrix on top. OE19 CAR-negative OE33
CAR-negative and respective vector-only controls were seeded onto the top well of the invasion chambers. Medium containing 10% FCS was added to the bottom well of the chambers, serving as a chemoattractant, whereas serum-free medium was used as a control. Following 24 h at 37 1C and 5% CO 2 , cells that had invaded the matrigel coated membrane (located at the lower membrane surface) were fixed and stained with a crystal violet solution containing 10% ethanol. Cells of three representative areas in each well were counted at a magnification of Â 100. Experiments were performed in triplicate and repeated at least twice.
Assessment of apoptosis in
esophageal cancer cells OE19 CAR-negative , OE33 CAR-negative , and respective vectoronly control cells were seeded into six-well plates at 2 Â 10 5 cells per well. Following 24 h cells were washed with PBS and new medium containing either recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; Biomol, Hamburg, Germany; 50 ng ml À1 ) no FCS, or 10% FCS (control) was added. Following cell cultivation for another 48 h the supernatant was collected, whereas adjacent cells were detached by trypsin treatment and suspended in medium. Supernatant and cell suspension were pooled. Following staining with trypan blue viable and dead cells were counted using a hematocytometer counting chamber (VWR International). Experiments were performed in triplicate and repeated at least twice.
Statistical methods
Statistical calculations were performed using Statistical Package for Social Sciences software (version 11.5; SPSS Inc., Chicago, IL). Relationships between CAR immunopositivity and clinicopathological features were evaluated using Fisher's exact probability test or w 2 -test, respectively. Statistical calculations on correlations between CAR status and esophageal adenocarcinoma cell proliferation, migration, invasion, and apoptosis were performed using Fisher's exact probability test (GraphPad Prism Software, version 4.00; GraphPad Software Inc., San Diego, CA).
Results
Expression and distribution of CAR in Barrett's esophagus and carcinoma
Immunohistochemical assessment of CAR expression showed a weak cytoplasmic signal in the basal layers of the normal esophageal squamous epithelium, which could not be differentiated from background staining by light microscopic examination. In contrast, suprabasal layers of the squamous epithelium were consistently CARnegative. In sharp contrast, unequivocal CAR expression was present in all samples of BE, low-grade IN and highgrade IN. No considerable differences in staining intensities according to the degree of IN were noted. Moreover, all cases of BC confined to the mucosa (T1m, n ¼ 4), resected endoscopically, displayed CAR immunoreactivity. Of the operative specimens, 93.1% displayed CAR immunopositivity. In 95.6% of these CAR-positive samples 80-100% of the epithelial cells showed CAR presence. On a subcellular level, CAR was found at the apical plasma membrane in all samples of BE, IN and immunopositive BC (Table 1; Figure 1 ). The correlation of CAR presence in the operative specimens with standard clinicopathological features did not reveal significant differences. However, CAR-negativity was found preferentially in more advanced, poorly differentiated cancers (Table 1) .
Impact of CAR on proliferation, migration, and invasion of esophageal carcinoma cells
To clarify the impact of CAR on crucial tumor-biological properties we performed a series of in vitro assays investigating esophageal adenocarcinoma cell lines OE19 and OE33 upon ectopic regulation of CAR expression. Both cell lines display equal levels of CAR protein expression as determined by western blotting. RNAimediated functional CAR knock down yielded clearly reduced CAR protein expression level in both cell lines. Proliferation assays employing these cell lines revealed a marked increase in cell numbers following 48 h of cultivation in OE19
CAR-negative and OE33 CAR-negative cells compared to the respective vector-only control cell lines (Figure 2a) . Furthermore, OE33
CAR-negative cells displayed a significant 65% increase in the number of migrating cells compared to the empty vector cell line control. To test whether cells migrate in a FCS-directed manner, FCSfree medium controls were included for each cell line. Hereby, no migration of either OE33 CAR-negative or OE33 control was noted (data not shown). Moreover, a significant increase in the number of invading cells was noted for the OE33 CAR-negative cell line compared with OE33 control cells (Figure 2b ). In contrast, neither the OE19 control cell line nor cells following functional CAR knock down (OE19 CAR-negative ) did migrate or invade in the respective assays (data not shown). CAR-negative cells also whereas for the OE33 CAR-negative cell line no significant differences were noted when compared to mock treated cells. However, neither TRAIL nor cultivation in FCS-free media did gain significant differences between vector-transfected controls and CAR-negative cell lines (Figure 3) . Figure 2 Impact of coxsackie and adenovirus receptor (CAR) on esophageal cancer cell proliferation, migration and invasion. Proliferation, migration and invasion in vitro assays were performed using OE19 and OE33 cells stably transfected with a CAR-specific siRNA compared to the respective 'vector-only' controls. CAR protein expression and siRNA-mediated knock down were determined by western blotting. Cell numbers were assessed following 48 h of cell culturing (a). Migration (upper panels presenting an entire, representative well) and invasion (lower panels showing typical areas at a magnification of Â 5, arrow marks invaded cells) were determined as outlined in Materials and methods section (b).
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Discussion
The objective of this study was to investigate presence of CAR in BE and BC to evaluate the potential use of CAR as target for adenovirus-based diagnostic and/or therapeutic strategies in these conditions. Moreover, we aimed to gain insight into the impact of CAR on pathogenesis of BE and BC. Therefore, we performed two different sets of experiments: (1) To determine expression of CAR in BE and BE-associated neoplasia we analyzed biopsy and resection specimens of both nonneoplastic and neoplastic BE. (2) To clarify whether loss of CAR influences functional characteristics of esophageal adenocarcinoma cells, as seen for other human cancer cell lines, we performed a series of in vitro assays upon CAR silencing by siRNA. On the basis of our findings of abundant, unequivocal CAR presence in BE and associated neoplasia we conclude that CAR may not serve as a useful diagnostic biomarker for these conditions, as neither the discrimination between BE and IN, nor between low and high-grade IN might be accomplished. In contrast, it may be suggested that CAR might impact the management of, for example, high-grade dysplasia and early stage esophageal carcinoma as therapeutic tool in addition to current treatment strategies such as surgical resection and endoscopic therapies. 28, 29 Hereby, attenuated adenoviruses, either replication-incompetent viruses delivering therapeutic genes or viruses that replicate restrictedly in cancer cells, may be employed that are currently under investigation in clinical trials. 3 As the esophagus allows for intraluminal, topic adenovirus application negative side effects of a systemic virus administration might be minimized. However, a previous study employing a rat model of BE showed that transduction of intraluminal administered fluorescence-labeled adenovirus was limited and preferentially localized to the basal layers of normal esophagus and stromal tissue within BE. 30 Furthermore, adenoviral transduction rates into freshly obtained esophageal adenocarcinoma biopsies were poor. 22 Nevertheless, both studies have employed model systems only, investigating small case numbers that may not sufficiently reflect the in vivo situation in humans.
Our results do support the concept of limited CAR expression in stratified esophageal epithelium as suggested by previous studies analyzing tissue samples of human (n ¼ 16) and murin origin, respectively. 5, 22, 31 In contrast to these reports and this study Heideman et al. 4 described high CAR expression in esophageal squamous epithelium employing immunohistochemistry. However, no information on CAR distribution within the esophageal epithelium is given. This may be of impact because restricted CAR immunopositivity has been seen previously and in this study within the basal layers. 5, 31 Furthermore, the use of the antibody RmcB, derived from a mouse hybridoma cell line, may explain the diverging results.
This study provides the first systematic assessment of CAR expression in the various stages of BE and BC, revealing abundant expression independently of the presence of neoplasia. To date reports on CAR immunopositivity in BE have been limited to a single patient. 22 Abundant CAR expression has also been found in other pre-and early malignant lesions: In early breast cancer (ductal carcinoma in situ) CAR has been detected diffusely at the plasma membrane and within the cytoplasm in contrast to 'normal' acini and ducts were CAR is restricted to cell-cell junctions.
14 Moreover, employing a three-dimensional cell culture system elevated CAR levels have been observed in a human breast cancer cell line compared to a nonmalignant control. Interestingly, this significant CAR upregulation could already be observed in breast cancer precursor cell lines, which are incapable of forming xenograft tumors in mice.
14 This may be similar to the CAR expression found in nonneoplastic BE, which represents a condition at risk for development of esophageal adenocarcinoma. Previously, it has been speculated that CAR promotes the early development of adenocarcinomas: CAR CAR in Barrett's esophagus M Anders et al overexpressing cell clones of cervical and ovarian cancer cells displayed less sensitivity toward apoptotic stimuli such as TRAIL, ultraviolet light, and serum withdrawal. 15 Thus, CAR has been assigned a protective role against endogenously produced death receptor ligands. In agreement with this hypothesis increased CAR expression has been seen upon transition from preneoplastic mammary lesions to invasive adenocarcinomas. 15 In contrast to these findings, no differences in CAR expression in regard to presence of neoplasia were detected in this study. Furthermore, no significant differences in cell viability were found in esophageal cancer cell lines following CAR inhibition compared to controls when subjected to apoptotic stimuli serum withdrawal or TRAIL treatment, respectively. Therefore, it may be speculated that CAR does neither facilitate a particular function during progression from nonneoplastic to neoplastic stages of BE, nor protect esophageal cancer cells against apoptosis. However, the employment of these cancer cell lines that have been assessable for our investigations may not properly reflect the situation in BE.
Our data do also reveal a tendency of CAR loss in a small subset of BC, preferentially in more advanced disease stages and tumors with undifferentiated histology. Reduced CAR expression has been previously demonstrated in other advanced carcinomas such as squamous esophageal cancer, prostate and bladder cancer. [5] [6] [7] [8] However, no significant correlation of CAR-negativity and standard clinicopathological characteristics were found in our analysis, which may be explained by the lack of late stage advanced and metastasizing cancers in our patient collective. Low CAR expression in esophageal adenocarcinoma compared to stratified epithelium have also been reported before. 4 However, as these authors do not provide information regarding tumor stage and number of investigated esophageal tissue specimens, no further conclusion can be made. To clarify whether loss of CAR may impact functional characteristics of esophageal adenocarcinomas we performed a series of in vitro assays upon siRNA-mediated functional knock down of CAR. These experiments revealed that reduced CAR expression promotes the proliferation of esophageal adenocarcinoma cells. This suggests an inhibitory function of CAR on tumor cell growth and is in line with previous observations in human glioma as well as bladder and prostate cancer cell lines. [10] [11] [12] Furthermore, we noted an increased migration and invasion of OE33 cells following CAR knock down. It may thus be speculated that CAR negatively impacts on these functions, a phenomenon that has already been seen in other tumor cell lines derived from gliomas, ovarian, and cervical cancers. 9, 10 However, no significant effect on these functions was seen in the OE19 cell line, limiting the extrapolation of our findings to the situation in vivo. The differences between the tested esophageal adenocarcinoma cell lines may indicate that the suppressive role of CAR on cancer cell migration and invasion depends critically on interactions with other proteins that potentially differ between cell lines. Moreover, no migration or invasion was noted for the OE19 control cell line in contrast to a small number of migrating and invading OE33 control cells. These findings indicate substantial differences in cell motility between these cell lines independent of the CAR status.
In summary, we demonstrate an upregulation of CAR in the various stages of BE and BC compared to 'normal' esophageal squamous epithelium. These findings suggest that adenovirus-based therapeutic strategies that use CAR as a virus-binding site could add to the current management of patients with esophageal adenocarcinoma and its precursors. Moreover, our data do indicate that loss of CAR may promote the progression of advanced esophageal adenocarcinomas.
Abbreviations BC, Barrett's carcinoma; BE, Barrett's esophagus; CAR, coxsackie and adenovirus receptor; IN, intraepithelial neoplasia; TJ, tight junction.
